CurifyLabs Secures $14 Million for 3D Printed Personalized Medicine

CurifyLabs, a Finnish health technology company, has announced the successful completion of a $14 million Series A funding round. This investment is earmarked for the expansion of its U.S. operations and the strengthening of its supply chain for its innovative 3D printing-enabled personalized medicine compounding system.

The company's proprietary Compounding System Solution (CSS) integrates specialized software, GMP-manufactured excipient bases, and 3D printing technology to automate the creation of tailored medications. Currently, pharmacies in both the U.S. and Europe utilize CurifyLabs' technology to compound and dispense thousands of doses daily.

The funding round was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures. U.S. customers and employees also contributed to the round. These funds will be directed towards the continued development of the CurifyLabs platform, including its latest product, the PharmaPrinter Aurum, which reportedly compounds medications up to nine times faster than traditional manual methods.

Charlotta Topelius, CEO and Founder of CurifyLabs, stated that the investment signifies the confidence partners have in their vision. She added, "We have set a high bar for clinical rigour, product quality, and customer support, and this funding gives us the resources to raise that bar further."